Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation

CONCLUSION: Results from this Delphi study clearly show an overall consensus on the use of adalimumab in the management of PsO and PsA, particularly as first-choice for specific subpopulations (uveitis, IBD, hidradenitis suppurativa). Considering the cost-effectiveness of biosimilars within Italy, adalimumab may represent an effective and safe first-line treatment for patients with moderate-to-severe PsO or PsA, and a valid choice for switching after failure.PMID:38571927 | PMC:PMC10985702 | DOI:10.1515/rir-2024-0006

Source: Cell Research - April 4, 2024 Category: Cytology Authors: Marco Matucci-Cerinic Francesco Ciccia Rosario Foti Alessandro Giunta Francesco Loconsole Francesca Prignano Rossana Scrivo Giampiero Girolomoni Source Type: research